JP2005533005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005533005A5 JP2005533005A5 JP2003577881A JP2003577881A JP2005533005A5 JP 2005533005 A5 JP2005533005 A5 JP 2005533005A5 JP 2003577881 A JP2003577881 A JP 2003577881A JP 2003577881 A JP2003577881 A JP 2003577881A JP 2005533005 A5 JP2005533005 A5 JP 2005533005A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- inhibitor
- drug
- inflammatory
- cox
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 230000001404 mediated effect Effects 0.000 claims 8
- 229940124597 therapeutic agent Drugs 0.000 claims 8
- 229940079593 drug Drugs 0.000 claims 6
- 108050006947 CXC Chemokine Proteins 0.000 claims 4
- 102000019388 CXC chemokine Human genes 0.000 claims 4
- 108010012236 Chemokines Proteins 0.000 claims 4
- 102000019034 Chemokines Human genes 0.000 claims 4
- 229940123907 Disease modifying antirheumatic drug Drugs 0.000 claims 4
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 4
- 239000005557 antagonist Substances 0.000 claims 4
- 239000002260 anti-inflammatory agent Substances 0.000 claims 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims 4
- 230000008512 biological response Effects 0.000 claims 4
- 229940111134 coxibs Drugs 0.000 claims 4
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 claims 4
- 239000002988 disease modifying antirheumatic drug Substances 0.000 claims 4
- 239000003018 immunosuppressive agent Substances 0.000 claims 4
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 claims 4
- 229960000485 methotrexate Drugs 0.000 claims 4
- 239000003607 modifier Substances 0.000 claims 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 4
- 229960002702 piroxicam Drugs 0.000 claims 4
- QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 claims 4
- -1 ruflunomide Chemical compound 0.000 claims 4
- 150000003431 steroids Chemical class 0.000 claims 4
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims 2
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 claims 2
- 101001027327 Bos taurus Growth-regulated protein homolog alpha Proteins 0.000 claims 2
- 102000016950 Chemokine CXCL1 Human genes 0.000 claims 2
- 229940122444 Chemokine receptor antagonist Drugs 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 claims 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 claims 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 claims 2
- 108010002352 Interleukin-1 Proteins 0.000 claims 2
- 108090001007 Interleukin-8 Proteins 0.000 claims 2
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 claims 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 229960002170 azathioprine Drugs 0.000 claims 2
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 2
- 159000000007 calcium salts Chemical class 0.000 claims 2
- 229960000590 celecoxib Drugs 0.000 claims 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 239000002559 chemokine receptor antagonist Substances 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 229960004544 cortisone Drugs 0.000 claims 2
- 229960004397 cyclophosphamide Drugs 0.000 claims 2
- 229930182912 cyclosporin Natural products 0.000 claims 2
- 230000016396 cytokine production Effects 0.000 claims 2
- 229960003957 dexamethasone Drugs 0.000 claims 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 2
- 229960001680 ibuprofen Drugs 0.000 claims 2
- 229960003444 immunosuppressant agent Drugs 0.000 claims 2
- 230000001861 immunosuppressant effect Effects 0.000 claims 2
- 229940124589 immunosuppressive drug Drugs 0.000 claims 2
- 229960000905 indomethacin Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000019189 interleukin-1 beta production Effects 0.000 claims 2
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims 2
- 229960000991 ketoprofen Drugs 0.000 claims 2
- 229940043355 kinase inhibitor Drugs 0.000 claims 2
- 239000003199 leukotriene receptor blocking agent Substances 0.000 claims 2
- HPNSFSBZBAHARI-UHFFFAOYSA-N micophenolic acid Natural products OC1=C(CC=C(C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-UHFFFAOYSA-N 0.000 claims 2
- 229950007856 mofetil Drugs 0.000 claims 2
- 229940014456 mycophenolate Drugs 0.000 claims 2
- HPNSFSBZBAHARI-RUDMXATFSA-N mycophenolic acid Chemical compound OC1=C(C\C=C(/C)CCC(O)=O)C(OC)=C(C)C2=C1C(=O)OC2 HPNSFSBZBAHARI-RUDMXATFSA-N 0.000 claims 2
- 229960002009 naproxen Drugs 0.000 claims 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 claims 2
- 229960001639 penicillamine Drugs 0.000 claims 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 claims 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims 2
- 229960005205 prednisolone Drugs 0.000 claims 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 2
- 229960004618 prednisone Drugs 0.000 claims 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims 2
- 230000000770 proinflammatory effect Effects 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 229960000371 rofecoxib Drugs 0.000 claims 2
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical group C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 159000000000 sodium salts Chemical class 0.000 claims 2
- SDKPSXWGRWWLKR-UHFFFAOYSA-M sodium;9,10-dioxoanthracene-1-sulfonate Chemical compound [Na+].O=C1C2=CC=CC=C2C(=O)C2=C1C=CC=C2S(=O)(=O)[O-] SDKPSXWGRWWLKR-UHFFFAOYSA-M 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims 2
- 229960001940 sulfasalazine Drugs 0.000 claims 2
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims 2
- 229960001967 tacrolimus Drugs 0.000 claims 2
- QJJXYPPXXYFBGM-SHYZHZOCSA-N tacrolimus Natural products CO[C@H]1C[C@H](CC[C@@H]1O)C=C(C)[C@H]2OC(=O)[C@H]3CCCCN3C(=O)C(=O)[C@@]4(O)O[C@@H]([C@H](C[C@H]4C)OC)[C@@H](C[C@H](C)CC(=C[C@@H](CC=C)C(=O)C[C@H](O)[C@H]2C)C)OC QJJXYPPXXYFBGM-SHYZHZOCSA-N 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 description 1
- 101000947174 Homo sapiens C-X-C chemokine receptor type 1 Proteins 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36531402P | 2002-03-18 | 2002-03-18 | |
| US60/365,314 | 2002-03-18 | ||
| PCT/US2003/008287 WO2003080053A1 (en) | 2002-03-18 | 2003-03-17 | Combination treatments for chemokine-mediated diseases |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005533005A JP2005533005A (ja) | 2005-11-04 |
| JP2005533005A5 true JP2005533005A5 (enExample) | 2010-05-27 |
| JP4733350B2 JP4733350B2 (ja) | 2011-07-27 |
Family
ID=28454639
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003577881A Expired - Fee Related JP4733350B2 (ja) | 2002-03-18 | 2003-03-17 | ケモカイン媒介疾患の併用治療 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20040053953A1 (enExample) |
| EP (1) | EP1485089B1 (enExample) |
| JP (1) | JP4733350B2 (enExample) |
| CN (1) | CN100444839C (enExample) |
| AR (1) | AR040400A1 (enExample) |
| AU (1) | AU2003220384B2 (enExample) |
| BR (1) | BR0308739A (enExample) |
| CA (1) | CA2479126C (enExample) |
| MX (1) | MXPA04009127A (enExample) |
| NO (1) | NO20044402L (enExample) |
| NZ (1) | NZ535314A (enExample) |
| TW (2) | TW200304811A (enExample) |
| WO (1) | WO2003080053A1 (enExample) |
| ZA (1) | ZA200407339B (enExample) |
Families Citing this family (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CZ20032831A3 (cs) * | 2001-04-16 | 2004-03-17 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony |
| JP2005505595A (ja) | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| WO2004033440A1 (en) | 2002-10-09 | 2004-04-22 | Schering Corporation | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
| EP1572029B1 (en) * | 2002-11-07 | 2010-03-24 | Abbott Laboratories | Method of loading beneficial agent to a prosthesis by fluid-jet application |
| US8524148B2 (en) * | 2002-11-07 | 2013-09-03 | Abbott Laboratories | Method of integrating therapeutic agent into a bioerodible medical device |
| US8221495B2 (en) * | 2002-11-07 | 2012-07-17 | Abbott Laboratories | Integration of therapeutic agent into a bioerodible medical device |
| JP4440917B2 (ja) | 2003-04-18 | 2010-03-24 | シェーリング コーポレイション | ２−ヒドロキシ−ｎ，ｎ−ジメチル−３−［［２−（１（ｒ）−５−メチル−２−フラニル）プロピル］アミノ］−３，４−ジオキソ−１−シクロブテン−１−イル］アミノ］ベンズアミドの合成 |
| ATE406356T1 (de) * | 2003-12-19 | 2008-09-15 | Schering Corp | Thiadiazole als cxc- und cc- chemokinrezeptorliganden |
| MXPA06007205A (es) | 2003-12-22 | 2006-08-31 | Schering Corp | Dioxidos de isotiazol como ligandos del receptor cxc y cc-quimiocina. |
| MY144657A (en) * | 2004-01-30 | 2011-10-31 | Schering Corp | Crystalline polymorphs of a cxc-chemokine receptor ligand. |
| DE102004016179A1 (de) * | 2004-03-30 | 2005-10-20 | Boehringer Ingelheim Pharma | Verbindungen zur Behandlung von proliferativen Prozessen |
| WO2005108989A2 (en) * | 2004-04-16 | 2005-11-17 | Genentech, Inc. | Assay for antibodies |
| US7326729B2 (en) * | 2004-05-12 | 2008-02-05 | Schering Corporation | CXCR1 and CXCR2 chemokine antagonists |
| AR049384A1 (es) * | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| CN101253165A (zh) * | 2005-06-29 | 2008-08-27 | 先灵公司 | 作为cxc－化学活素受体配体的二取代的二唑 |
| JP2009500328A (ja) | 2005-06-29 | 2009-01-08 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターリガンドとしての５，６−ジ−置換オキサジアゾロピラジンおよびチアジアゾロピラジン |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| EP2026770A1 (en) * | 2006-06-12 | 2009-02-25 | Schering Corporation | Pharmaceutical formulations and compositions of a selective antagonist of either cxcr2 or both cxcr1 and cxcr2 and methods of using the same for treating inflammatory disorders |
| EP2041107A1 (en) * | 2006-07-07 | 2009-04-01 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) * | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| MX2009013276A (es) | 2007-06-06 | 2010-01-25 | Novartis Ag | Compuestos anti-inflamatorios de ciclobutenodiona sustituida. |
| CN101932553A (zh) * | 2007-07-03 | 2010-12-29 | 先灵公司 | 合成1,2-取代的3,4-二氧代-1-环丁烯化合物的方法和中间体 |
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| WO2010131147A1 (en) * | 2009-05-12 | 2010-11-18 | Pfizer Limited | Cyclobutenedione derivatives |
| FR2961695B1 (fr) * | 2010-06-29 | 2012-07-06 | Galderma Res & Dev | Utilisation de composes dans le traitement ou la prevention de troubles cutanes |
| US20140170112A1 (en) * | 2011-03-12 | 2014-06-19 | Vicus Therapeutics, Llc | Compositions for ameliorating systemic inflammation and methods for making and using them |
| PT2760821T (pt) | 2011-09-02 | 2018-01-11 | Novartis Ag | Sal de colina de um composto anti-inflamatório de ciclobutenodiona substituída |
| FR2981934B1 (fr) * | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| KR101306199B1 (ko) * | 2012-01-31 | 2013-09-09 | 부산대학교 산학협력단 | 포스포리파아제 ｄ 억제제를 유효성분으로 포함하는 골다공증 예방 및 치료용 약학적 조성물 |
| US8865723B2 (en) | 2012-10-25 | 2014-10-21 | Tetra Discovery Partners Llc | Selective PDE4 B inhibition and improvement in cognition in subjects with brain injury |
| US9763992B2 (en) | 2014-02-13 | 2017-09-19 | Father Flanagan's Boys' Home | Treatment of noise induced hearing loss |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| RU2020106383A (ru) | 2017-08-14 | 2021-09-16 | Аллерган, Инк. | 3,4-двузамещенные 3-циклобутен-1,2-дионы и их применение |
| NZ763299A (en) * | 2017-09-14 | 2025-09-26 | Daiichi Sankyo Co Ltd | Compound having cyclic structure |
| IL275839B2 (en) | 2018-01-08 | 2024-02-01 | Chemocentryx Inc | Methods for the treatment of generalized abscess psoriasis using a CCR6 or CXCR2 antagonist |
| GEP20237476B (en) | 2018-09-21 | 2023-03-27 | Pfizer | N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors |
| CN112851635B (zh) * | 2019-11-28 | 2022-09-16 | 中国医学科学院药物研究所 | 环状砜类化合物及其制备方法、用途和药物组合物 |
| EP3868368A1 (en) * | 2020-02-21 | 2021-08-25 | Dompe' Farmaceutici S.P.A. | Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof |
| WO2025092968A1 (zh) * | 2023-11-03 | 2025-05-08 | 武汉朗来科技发展有限公司 | 作为ccr6拮抗剂的化合物、其药物组合物和用途 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1531943A (fr) | 1966-07-28 | 1968-07-05 | Huels Chemische Werke Ag | Procédé pour stabiliser des poly-acétals macromoléculaires |
| DE1669798A1 (de) | 1966-07-28 | 1971-08-26 | Huels Chemische Werke Ag | Verfahren zum Stabilisieren markomolekularer Polyacetale |
| DE2638855C3 (de) | 1976-08-28 | 1980-04-24 | Chemische Werke Huels Ag, 4370 Marl | Verwendung von Quadratsäureamiden als Stabilisierungsmittel für geformte oder nicht geformte Kunststoffe |
| CS214745B2 (en) * | 1976-08-28 | 1982-05-28 | Huels Chemische Werke Ag | Shaped and non-shaped products from plastic materials |
| DE3309655A1 (de) | 1983-03-17 | 1984-09-20 | Bayer Ag, 5090 Leverkusen | 1,2,5-thiadiazol-1-oxide und 1,1-dioxide, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| JPS60255756A (ja) * | 1984-06-01 | 1985-12-17 | Ikeda Mohandou:Kk | アミノアルキルフエノキシ誘導体 |
| US4978665A (en) | 1987-01-20 | 1990-12-18 | Nissan Chemical Industries Ltd. | 3(2H)pyridazinone, and antagonistic agent against SRS-A containing it |
| JPH02256668A (ja) | 1988-12-20 | 1990-10-17 | Nissan Chem Ind Ltd | ピリダジノン誘導体 |
| US5206252A (en) * | 1992-05-08 | 1993-04-27 | American Home Products Corporation | Thiadiazolyl-amino derivatives of benzopyrans and indanes |
| GB9312210D0 (en) | 1993-06-14 | 1993-07-28 | Smithkline Beecham Plc | Chemical compounds |
| US5354763A (en) * | 1993-11-17 | 1994-10-11 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5506252A (en) * | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| US5466712A (en) * | 1994-11-04 | 1995-11-14 | American Home Products Corporation | Substituted n-aryl-1,2-diaminocyclobutene-3,4-diones |
| ES2128774T3 (es) | 1994-11-16 | 1999-05-16 | American Home Prod | Diaminociclobuten-3,4-dionas. |
| HUP0001943A3 (en) * | 1997-01-23 | 2002-12-28 | Smithkline Beecham Corp | Benzimidazole and benzotriazole derivatives, their use, process for their preparation and pharmaceutical compositions containing them |
| US5840764A (en) * | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AU6250298A (en) | 1997-01-30 | 1998-08-25 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AR015425A1 (es) * | 1997-09-05 | 2001-05-02 | Smithkline Beecham Corp | Compuestos de benzotiazol, composicion farmaceutica que los contiene, su uso en la manufactura de un medicamento, procedimiento para su preparacion,compuestos intermediarios y procedimiento para su preparacion |
| AU5727899A (en) | 1998-10-02 | 2000-04-26 | Neurosearch A/S | Diaminocyclobutene-3,4-dione derivatives, their preparation and use |
| EP1119548B1 (en) | 1998-10-08 | 2004-12-08 | SmithKline Beecham plc | 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione as glycogen synthase kinase-3 inhibitor (gsk-3) |
| US6376555B1 (en) * | 1998-12-04 | 2002-04-23 | American Home Products Corporation | 4-substituted-3-substituted-amino-cyclobut-3-ene-1,2-diones and analogs thereof as novel potassium channel openers |
| BR9916211A (pt) | 1998-12-14 | 2001-09-11 | American Home Prod | Derivados de 3,4-diamino-3-ciclobuteno-1,2-diona que inibem adesão de leucócito mediada por vla-4 |
| US6420396B1 (en) * | 1998-12-16 | 2002-07-16 | Beiersdorf Ag | Biphenyl and biphenyl-analogous compounds as integrin antagonists |
| JP2002532465A (ja) | 1998-12-16 | 2002-10-02 | バイエル アクチェンゲゼルシャフト | インテグリンアンタゴニストとしての新規なビフェニル及びビフェニル−類似化合物 |
| US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
| EP1220840A2 (en) | 1999-10-15 | 2002-07-10 | Bristol-Myers Squibb Pharma Company | Bicyclic and tricyclic amines as modulators of chemokine receptor activity |
| EP1265905A4 (en) | 2000-03-01 | 2003-03-12 | Smithkline Beecham Corp | IL-2 RECEPTOR ANTAGONISTS |
| AR033803A1 (es) * | 2000-03-01 | 2004-01-07 | Smithkline Beecham Corp | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas |
| EP1274415A4 (en) | 2000-03-14 | 2005-09-07 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| MY120279A (en) * | 2000-05-26 | 2005-09-30 | Pharmacia Corp | Use of a celecoxib composition for fast pain relief |
| MXPA02011868A (es) * | 2000-05-30 | 2003-04-10 | Smithkline Beecham Corp | Antagonistas de receptor de interleucina 8. |
| US20040132694A1 (en) * | 2001-01-16 | 2004-07-08 | Palovich Michael R. | Il-8 receptor antagonists |
| US20040048897A1 (en) * | 2001-01-16 | 2004-03-11 | Mccleland Brent | Il-8 receptor antagonists |
| US20030204085A1 (en) * | 2001-02-02 | 2003-10-30 | Taveras Arthur G. | 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists |
| NZ527947A (en) * | 2001-02-02 | 2005-10-28 | Schering Corp | 3,4-di-substituted cyclobutene-1,2-diones as CXC chemokine receptor antagonists |
| CZ20032831A3 (cs) * | 2001-04-16 | 2004-03-17 | Schering Corporation | 3,4-Disubstituované cyklobuten-1,2-diony |
| US7132445B2 (en) * | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| JP2005505595A (ja) * | 2001-10-12 | 2005-02-24 | シェーリング コーポレイション | Ｃｘｃ−ケモカインレセプターアンタゴニストとしての３，４−二置換マレイミド化合物 |
| US6878709B2 (en) * | 2002-01-04 | 2005-04-12 | Schering Corporation | 3,4-di-substituted pyridazinediones as CXC chemokine receptor antagonists |
| JP4836388B2 (ja) | 2002-03-22 | 2011-12-14 | 第一三共株式会社 | ｅＮＯＳ発現に起因する疾患の予防または治療薬 |
| WO2004033440A1 (en) * | 2002-10-09 | 2004-04-22 | Schering Corporation | Thiadiazoledioxides and thiadiazoleoxides as cxc- and cc-chemokine receptor ligands |
-
2003
- 2003-03-17 CN CNB038106183A patent/CN100444839C/zh not_active Expired - Fee Related
- 2003-03-17 NZ NZ535314A patent/NZ535314A/en not_active IP Right Cessation
- 2003-03-17 BR BR0308739-5A patent/BR0308739A/pt not_active IP Right Cessation
- 2003-03-17 JP JP2003577881A patent/JP4733350B2/ja not_active Expired - Fee Related
- 2003-03-17 US US10/390,078 patent/US20040053953A1/en not_active Abandoned
- 2003-03-17 EP EP03716685.7A patent/EP1485089B1/en not_active Expired - Lifetime
- 2003-03-17 MX MXPA04009127A patent/MXPA04009127A/es unknown
- 2003-03-17 WO PCT/US2003/008287 patent/WO2003080053A1/en not_active Ceased
- 2003-03-17 AU AU2003220384A patent/AU2003220384B2/en not_active Ceased
- 2003-03-17 CA CA2479126A patent/CA2479126C/en not_active Expired - Fee Related
- 2003-03-18 AR AR20030100943A patent/AR040400A1/es not_active Application Discontinuation
- 2003-03-18 TW TW092105892A patent/TW200304811A/zh unknown
- 2003-03-18 TW TW096114061A patent/TW200808314A/zh unknown
-
2004
- 2004-09-13 ZA ZA200407339A patent/ZA200407339B/en unknown
- 2004-10-15 NO NO20044402A patent/NO20044402L/no not_active Application Discontinuation
-
2007
- 2007-02-14 US US11/705,929 patent/US7960433B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005533005A5 (enExample) | ||
| CN100444839C (zh) | 式(i)化合物在制备治疗化学激活物中介的疾病的药物中的应用 | |
| ES2337241T3 (es) | Derivados de piperazina con actividad antagonista de receptores ccr1. | |
| JP5746981B2 (ja) | Ｊａｋキナーゼ調節キナゾリン誘導体、及びその使用方法 | |
| JP2005194283A5 (enExample) | ||
| CN100496493C (zh) | 2-氨基-4,5-三取代噻唑基衍生物 | |
| JP2005533809A5 (enExample) | ||
| JP5932848B2 (ja) | アモルファス（５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸 | |
| CN1215991A (zh) | 霉酚酸盐的包有肠溶衣的药物组合物 | |
| JP5901634B2 (ja) | キナゾリン化合物及びその使用方法 | |
| JP2007530577A5 (enExample) | ||
| JP2010500360A5 (enExample) | ||
| CN101511809A (zh) | 作为cxc-趋化因子受体配体的3,4-二取代的环丁烯-1,2-二酮 | |
| JP2005509597A5 (enExample) | ||
| WO2009063202A2 (en) | Use of crth2 antagonist compounds | |
| PT2642999T (pt) | Métodos de tratamento que utilizam inibidores seletivos de bcl-2 | |
| JP2016164177A5 (enExample) | ||
| JP2006523216A5 (enExample) | ||
| JP2005515964A5 (enExample) | ||
| WO2006119958A2 (en) | Use of flibanserin in the treatment of chronic pain | |
| JP2006515299A5 (enExample) | ||
| BR112021003613A2 (pt) | conjugados de isoquinolina-esteróides e seus usos | |
| JP2023526304A (ja) | コロナウイルス感染症治療のためのｔｌｒ７／８拮抗薬 | |
| JP2004529117A5 (enExample) | ||
| JP2002326936A5 (enExample) |